SUMMARY: The extent to which fracture protection and safety varies with increasing time on teriparatide [rhPTH(1-34)] therapy is a clinically relevant unanswered question. In postmenopausal women with osteoporosis, increased duration of teriparatide versus placebo treatment was associated with a progressive decrease in the rates of nonvertebral fragility fractures and back pain. INTRODUCTION: The impact of duration of teriparatide [rhPTH(1-34)] therapy on patient outcomes is a relevant unanswered question. METHODS:Postmenopausal women with osteoporosis were randomized to once-daily subcutaneous injection with placebo (N = 544), teriparatide 20 microg (TPTD20; N = 541), or teriparatide 40 microg (TPTD40; N = 552) plus calcium and vitamin D supplementation. The time to first nonvertebral fragility fracture and new or worsening back pain following treatment initiation was analyzed using Cox partial likelihood regression treating time on therapy as a linear, time-dependent covariate. RESULTS: Compared with placebo, the relative hazard for nonvertebral fragility fractures decreased by 7.3% for each additional month of TPTD20 [hazard ratio = 0.927, 95% CI (0.876 to 0.982), p = 0.009] and by 7.6% for each additional month of TPTD40 [hazard ratio = 0.924, 95% CI (0.871 to 0.981), p = 0.009]. Clinical vertebral fractures appeared to increase over time in the placebo group and occurred primarily in the first time interval in the teriparatide treatment groups. Compared with placebo, the relative hazard of back pain was decreased by 8.3% for each additional month of TPTD20 [hazard ratio = 0.920, 95% CI (0.902 to 0.939), p < 0.001] and 8.7% for each additional month of TPTD40 [hazard ratio = 0.917, 95% CI (0.898 to 0.935), p < 0.001]. CONCLUSIONS: These findings suggest increased nonvertebral fracture protection, reduced back pain, and reduced occurrence of side effects with longer duration of teriparatide therapy.
RCT Entities:
SUMMARY: The extent to which fracture protection and safety varies with increasing time on teriparatide [rhPTH(1-34)] therapy is a clinically relevant unanswered question. In postmenopausal women with osteoporosis, increased duration of teriparatide versus placebo treatment was associated with a progressive decrease in the rates of nonvertebral fragility fractures and back pain. INTRODUCTION: The impact of duration of teriparatide [rhPTH(1-34)] therapy on patient outcomes is a relevant unanswered question. METHODS: Postmenopausal women with osteoporosis were randomized to once-daily subcutaneous injection with placebo (N = 544), teriparatide 20 microg (TPTD20; N = 541), or teriparatide 40 microg (TPTD40; N = 552) plus calcium and vitamin D supplementation. The time to first nonvertebral fragility fracture and new or worsening back pain following treatment initiation was analyzed using Cox partial likelihood regression treating time on therapy as a linear, time-dependent covariate. RESULTS: Compared with placebo, the relative hazard for nonvertebral fragility fractures decreased by 7.3% for each additional month of TPTD20 [hazard ratio = 0.927, 95% CI (0.876 to 0.982), p = 0.009] and by 7.6% for each additional month of TPTD40 [hazard ratio = 0.924, 95% CI (0.871 to 0.981), p = 0.009]. Clinical vertebral fractures appeared to increase over time in the placebo group and occurred primarily in the first time interval in the teriparatide treatment groups. Compared with placebo, the relative hazard of back pain was decreased by 8.3% for each additional month of TPTD20 [hazard ratio = 0.920, 95% CI (0.902 to 0.939), p < 0.001] and 8.7% for each additional month of TPTD40 [hazard ratio = 0.917, 95% CI (0.898 to 0.935), p < 0.001]. CONCLUSIONS: These findings suggest increased nonvertebral fracture protection, reduced back pain, and reduced occurrence of side effects with longer duration of teriparatide therapy.
Authors: Yanfei L Ma; Qingqiang Zeng; David W Donley; Louis-Georges Ste-Marie; J Christopher Gallagher; Gail P Dalsky; Robert Marcus; Erik Fink Eriksen Journal: J Bone Miner Res Date: 2006-06 Impact factor: 6.741
Authors: Michael C Nevitt; Peiqi Chen; Robin K Dore; Jean-Yves Reginster; Douglas P Kiel; Jose R Zanchetta; Emmett V Glass; John H Krege Journal: Osteoporos Int Date: 2005-09-02 Impact factor: 4.507
Authors: D W Dempster; F Cosman; E S Kurland; H Zhou; J Nieves; L Woelfert; E Shane; K Plavetić; R Müller; J Bilezikian; R Lindsay Journal: J Bone Miner Res Date: 2001-10 Impact factor: 6.741
Authors: Robert Lindsay; Wim H Scheele; Robert Neer; Gerhardt Pohl; Silvano Adami; Carlos Mautalen; Jean-Yves Reginster; Jan J Stepan; Stephen L Myers; Bruce H Mitlak Journal: Arch Intern Med Date: 2004-10-11
Authors: Yebin Jiang; Jenny J Zhao; Bruce H Mitlak; Ouhong Wang; Harry K Genant; Erik F Eriksen Journal: J Bone Miner Res Date: 2003-11 Impact factor: 6.741
Authors: J Reeve; P J Meunier; J A Parsons; M Bernat; O L Bijvoet; P Courpron; C Edouard; L Klenerman; R M Neer; J C Renier; D Slovik; F J Vismans; J T Potts Journal: Br Med J Date: 1980-06-07
Authors: P Hadji; J R Zanchetta; L Russo; C P Recknor; K G Saag; F E McKiernan; S L Silverman; J Alam; R T Burge; J H Krege; M C Lakshmanan; D N Masica; B H Mitlak; J L Stock Journal: Osteoporos Int Date: 2011-12-13 Impact factor: 4.507
Authors: Joel S Finkelstein; Jason J Wyland; Benjamin Z Leder; Sherri-Ann M Burnett-Bowie; Hang Lee; Harald Jüppner; Robert M Neer Journal: J Clin Endocrinol Metab Date: 2009-04-28 Impact factor: 5.958
Authors: Bente L Langdahl; Gerald Rajzbaum; Franz Jakob; Dimitrios Karras; Osten Ljunggren; Willem F Lems; Astrid Fahrleitner-Pammer; J Bernard Walsh; Clare Barker; Alexey Kutahov; Fernando Marin Journal: Calcif Tissue Int Date: 2009-10-13 Impact factor: 4.333